Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of January 2025

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1

Trading Halt

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Alterity Therapeutics Limited
	By:	/s/ Geoffrey P. Kempler
		Geoffrey P. Kempler
		Chairman

 

Date: January 28, 2025

 

 

2

 

Exhibit 99.1

 

 

Market Announcement

 

28 January 2025

 

 

 

Alterity Therapeutics Limited (ASX: ATH) – Trading Halt

 

Description

 

The securities of Alterity Therapeutics Limited (‘ATH’) will be placed in trading halt at the request of ATH, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 30 January 2025 or when the announcement is released to the market.

 

Issued by

 

ASX Compliance

 

28 January 2025		Market Announcement 1/1
ASX Limited		ASX Customer Service Centre 131 279 | asx.com.au

 

 

 

 

 

28 January 2025

 

By email: [e-mail]

 

Melissa Kostopoulos

Adviser, Listings Compliance (Melbourne) ASX Limited

 

Dear Melissa

 

Request for a trading halt

 

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (the Company), requests that the Company’s securities be placed into a trading halt with immediate effect.

 

For the purposes of Listing Rule 17.1, the Company provides the following information:

 

1.

(a) the Company is seeking the trading halt pending an announcement in relation to the results of its Phase II clinical trial;

 

2.

(b) the Company requests that the trading halt continues until the earlier of it making an announcement regarding the results of the Phase II clinical trial or until the commencement of trading on Thursday 30 January 2025; and

 

3.

(c) the Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

 

Please contact us should you have any questions.

 

Yours sincerely

 

/s/ Abby Macnish Niven

Abby Macnish Niven

Company Secretary

For and on behalf of the Board of Alterity Therapeutics Limited

 

Alterity Therapeutics Limited

Level 3, 460 Bourke Street, Melbourne, VIC 3000 Australia

T: [phone] | WWW.alteritytherapeutics.com

 

 

 

 

---